Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies Intest Res. 2023;22(2):172-185 Ulcerative colitis (UC) is a chronic relapsing disease characterized by mucosal inflammation of the colon. The goal of UC treatment is to induce and maintain remission. Despite significant therapeutic advances, current treatments have limited or lose clinical efficacy over time. Mirikizumab is a humanized immunoglobulin G4–variant monoclonal antibody that specifically binds to the p19 subunit of IL23. LUCENT-1 and LUCENT-2 demonstrated mirikizumab was more effective compared with placebo in inducing and maintaining clinical remission in patients with moderately to severely active UC. Would mirikizumab actually be effective in Far East Asian UC patients? The present study evaluated the efficacy and safety of mirikizumab in a Japanese subpopulation with moderately to severely active UC from the LUCENT-1 and LUCENT-2 studies. A total of 137 patients enrolled in Japan were randomized to mirikizumab (n = 102) or placebo (n = 35). Mirikizumab induction and maintenance treatments were effective in Japanese patients with moderately to severely active UC and no new safety issues have been identified. ![]()
Best regards, |